Mycophenolate mofetil can be used as monotherapy late after liver transplantation.
Moreno Planas, Jose Maria; Cuervas-Mons Martinez, Valentin; Rubio Gonzalez, Eduardo; Gomez Cruz, Amparo; Lopez-Monclus, Javier; Sánchez-Turrion, Victor; Lucena Poza, Jose Luis; Jimenez Garrido, Manuel; Millan, Isabel.
Am J Transplant
; 4(10): 1650-5, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15367220
Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysisâ©.
Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients.
Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials.
Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Current State of Immunosuppression: Past, Present, and Future.
Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.